{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:26:31Z","timestamp":1699971991533},"reference-count":26,"publisher":"Wiley","issue":"s8","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Management of gastro\u2010oesophageal reflux disease (GERD) is aimed at reducing oesophageal acid exposure to achieve symptom relief. Therapy has traditionally included advice to the patient on diet and lifestyle management. Recent evidence suggests, however, that some specific dietary modifications may be applicable to the Japanese patient. For example, ingestion of Japanese sweet cakes or rice cakes should be avoided by the Japanese patient with GERD as these foods may provoke heartburn. Pharmacological therapy is, however, usually also required for effective symptom relief. While antacids and histamine H<jats:sub>2<\/jats:sub>\u2010receptor antagonists have a role in treating mild GERD, effective relief of many cases of oesophagitis is usually only achieved by using proton\u2010pump inhibitors such as lansoprazole, omeprazole and rabeprazole. In the Japanese population, variation in the genetic polymorphism of CYP2C19 (a cytochrome P450 isoenzyme) leads to considerable inter\u2010individual unpredictability in the activity of lansoprazole and omeprazole due to inter\u2010individual differences in the extent to which these agents are metabolized. Consequently, rabeprazole, which does not undergo hepatic biotransformation by CYP2C19, offers significant advantages over the other PPIs as a result of its more predictable activity. This, coupled with its more rapid onset of action, leads to a more efficient and less variable acid\u2010suppressing effect.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02223.x","type":"journal-article","created":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T14:32:14Z","timestamp":1101911534000},"page":"19-23","source":"Crossref","is-referenced-by-count":9,"title":["Review article: treatment for gastro\u2010oesophageal reflux disease \u2013 lifestyle advice and medication"],"prefix":"10.1111","volume":"20","author":[{"given":"Y.","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,12]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"497","article-title":"Are oesophageal symptoms reflux\u2010related? A study of different scoring systems in a cohort of different patients with heartburn","volume":"89","author":"Johnston B","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_3_2","first-page":"3S","article-title":"The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defence, dysmotility, and acid exposure","volume":"92","author":"Orlando RC","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_4_2","first-page":"128","article-title":"Gastroesophageal reflux disease \u2013 state of the art","volume":"1","author":"Katz PO","year":"2001","journal-title":"Rev Gastroenterol Disorders"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(99)00179-3"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.8.1020"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199606000-00020"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(00)01968-7"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90021-3"},{"key":"e_1_2_7_10_2","first-page":"A361(Abstract","article-title":"Provocation of transient lower esophageal sphincter relaxations and gastroesophageal reflux by intraduodenal fat","volume":"98","author":"Ireland A","year":"1990","journal-title":"Gastroneterology"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.1.39"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02617.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(99)00760-1"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03041.x"},{"key":"e_1_2_7_15_2","first-page":"1881","article-title":"[Cost effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine\u20102\u2010receptor antagonist \u2013 Article in Japanese]","volume":"58","author":"Habu Y","year":"2000","journal-title":"Nippon Rinsho"},{"key":"e_1_2_7_16_2","first-page":"1330","article-title":"[Randomized controlled comparative study of PPI and H2RA for the treatment of reflux esophagitis \u2013 article in Japanese]","volume":"21","author":"Kawano S","year":"2002","journal-title":"Ther Res"},{"key":"e_1_2_7_17_2","first-page":"1387","article-title":"[Clinical evaluation of omeprazole in treating H2 receptor antagonist reflux esophagitis (II) \u2013 relapse prevention and safety \u2013 Article in Japanese]","volume":"16","author":"Sekiguchi T","year":"2000","journal-title":"J Clin Ther Med"},{"key":"e_1_2_7_18_2","first-page":"1067","article-title":"[Cost\u2010effectiveness for the treatment of reflux esophagitis: (I) PPI first strategy versus \u2018step\u2010up\u2019 strategy for acute treatment (II) PPI versus H2RA for maintenance treatment \u2013 Article in Japanese]","volume":"22","author":"Habu Y","year":"2001","journal-title":"Ther Res"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80032-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03675.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00019.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00394.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01348.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03190.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00022.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200106000-00009"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00840.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02223.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02223.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02223.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:36:58Z","timestamp":1695807418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02223.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":26,"journal-issue":{"issue":"s8","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02223.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02223.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}